Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study

Acta Oncologica

Volumn 51, Issue 2, 2012, Pages 254-261

  Cronin Fenton, Deirdre P ^a   Hellberg, Ylva ^a   Lauridsen, Kristina L ^a   Ahern, Thomas P ^b   Garne, Jens Peter ^c   Rosenberg, Carol ^d   Silliman, Rebecca A ^d,e   Sørensen, Henrik Toft ^a   Lash, Timothy L ^a,e   Hamilton Dutoit, Stephen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PARAFFIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DENMARK; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURGICAL TECHNIQUE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856485431     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.633556     Document Type: Article

References (29)

1. Jordan VC. Tamoxifen: Catalyst for the change to targeted therapy. Eur J Cancer 2008;44:30-8.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-67.
3. Goussard J. Paraffi n section immunocytochemistry and cytosol-based ligand-binding assays for ER and PR detection in breast cancer: The time has come for more objectivity. Cancer Lett 1998;132:61-6.
4. Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, et al. Estrogen receptor immunocytochemistry in paraffi n embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligandbinding assays. Cancer 1996;77:2514-9.
5. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17: 1474-81.
6. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffi n-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990;26:442-9.
7. Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, et al. Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: Evaluation of discordant fi ndings. Breast Cancer Res Treat 1998;50:125-34.
8. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25: 3846-52.
9. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 2008;100:218-21.
10. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008;26:2473-81.
11. Khoshnoud MR, Lofdahl B, Fohlin H, Fornander T, Stal O, Skoog L, et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat Epub 2010 Oct 19.
12. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011;103:489-500.
13. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010;49:305-12.
14. Talman ML, Rasmussen BB, Andersen J, Christensen IJ. Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol 2008;47:789-94.
15. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506-24.
16. Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
17. Frank L. Epidemiology. When an entire country is a cohort. Science 2000;287:2398-9.
18. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: The Danish National Pathology Registry and Data Bank. Clin Epidemiol 2010;2:51-6.
19. Andersen J, Bentzen SM, Poulsen HS. Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol 1988;24:377-84.
20. Andersen J. Determination of estrogen receptors in paraffi nembedded tissue. Techniques and the value in breast cancer treatment. Acta Oncol 1992;31:611-27.
21. K houry T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fi xation effect on breast biomarkers. Mod Pathol 2009;22:1457-67.
22. Golouh R, Vrhovec I, Bracko M, Frkovic-Grazio S. Comparison of standardized immunohistochemical and biochemical assays for estrogen and progesterone receptors in breast carcinoma. Pathol Res Pract 1997;193:543-9.
23. Ahern TP, Larsson H, Garne JP, Cronin-Fenton DP, Sorensen HT, Lash TL. Trends in breast-conserving surgery in Denmark, 1982 - 2002. Eur J Epidemiol 2008;23:109-14.
24. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20: 1319-29.
25. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/ College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
26. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfi eld M, Dranitsaris G, et al. Does confi rmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-504.
27. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010;21:1254-61.
28. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triplereceptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953 - 8.
29. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9.